France's Fluofarma and Roche Ink High-Content Assay Development Deal | GenomeWeb

NEW YORK (GenomeWeb News) – French high-content screening vendor Fluofarma said recently that it has entered into a multi-year assay development agreement with Roche.

Under the terms of the partnership, Roche and Fluofarma will work together to develop miniaturized cell-based assays using high-throughput flow cytometry and computational models to improve the predictability of hepatotoxicity and safety profiling of compounds in liver cells.

Financial terms of the partnership were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.